Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 3 2Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 3Lymphoid 3Gastrointestinal 2Sarcoma 1Myeloid 1Head & Neck 1Gynecologic 1Genitourinary 1Classical hematology 1CNS 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Breast Neoplasms, Male 1Breast Neoplasms 1

Interventions

Trastuzumab 71Paclitaxel 63Cyclophosphamide 56pembrolizumab 53Fulvestrant 42Carboplatin 40Capecitabine 37Docetaxel 32Letrozole 27Doxorubicin 23palbociclib 21pertuzumab 19Nivolumab 18eribulin 17abemaciclib 17ribociclib 16Gemcitabine 16130-nm albumin-bound paclitaxel 16durvalumab 15Everolimus 15Albumin-Bound Paclitaxel 15sacituzumab govitecan 14Lapatinib 14Filgrastim 14fludarabine 13exemestane 13Taxes 13Bevacizumab 13Cisplatin 12olaparib 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Microarray Analysis × Breast × Clear all
NCT01105312 2017-06-27

Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer

Alliance for Clinical Trials in Oncology

Phase 1/2 Completed
28 enrolled 13 charts
Breast

Breast Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡